Search

Your search keyword '"Bardazzi, F."' showing total 825 results
Start Over Author "Bardazzi, F."
825 results on '"Bardazzi, F."'

209. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study

Author

Giovanni Pellacani, Annamaria Offidani, Aurora Parodi, Alina De Rosa, Martina Burlando, Maria Concetta Fargnoli, Alessandro Zullo, Emanuela Zagni, Federico Bardazzi, Eugenio Provenzano, Chiara Moltrasio, Lucia Simoni, Piergiorgio Malagoli, Delia Colombo, Andrea Conti, Luca Stingeni, Michela Ortoncelli, Giuseppe Argenziano, Salvatore Corrao, Annalisa Tonini, Francesca Gaiani, Katharina Hansel, Marina Talamonti, Matteo Megna, Ketty Peris, Matteo Paolinelli, Rosaria Fidanza, Gabriella Fabbrocini, Clara De Simone, Antonio Costanzo, Marco Adriano Chessa, Luca Bianchi, Alessandra Narcisi, Massimo Raspanti, Paolo Dapavo, Marco Romanelli, C. Carrera, M. Fiocchi, Silvana Ruffolo, Zagni, E., Bianchi, L., Fabbrocini, G., Corrao, S., Offidani, A., Stingeni, L., Costanzo, A., Pellacani, G., Peris, K., Bardazzi, F., Argenziano, G., Ruffolo, S., Dapavo, P., Carrera, C., Fargnoli, M. C., Parodi, A., Romanelli, M., Malagoli, P., Talamonti, M., Megna, M., Raspanti, M., Paolinelli, M., Hansel, K., Narcisi, A., Conti, A., De Simone, C., Chessa, M. A., De Rosa, A., Provenzano, E., Ortoncelli, M., Moltrasio, C., Fidanza, R., Burlando, M., Tonini, A., Gaiani, F. M., Simoni, L., Zullo, A., Fiocchi, M., Colombo, D., Zagni, Emanuela, Bianchi, Luca, Fabbrocini, Gabriella, Corrao, Salvatore, Offidani, Annamaria, Stingeni, Luca, Costanzo, Antonio, Pellacani, Giovanni, Peris, Ketty, Bardazzi, Federico, Argenziano, Giuseppe, Ruffolo, Silvana, Dapavo, Paolo, Carrera, Carlo, Fargnoli, Maria Concetta, Parodi, Aurora, Romanelli, Marco, Malagoli, Piergiorgio, Talamonti, Marina, Megna, Matteo, Raspanti, Massimo, Paolinelli, Matteo, Hansel, Katharina, Narcisi, Alessandra, Conti, Andrea, De Simone, Clara, Chessa, Marco Adriano, De Rosa, Alina, Provenzano, Eugenio, Ortoncelli, Michela, Moltrasio, Chiara, Fidanza, Rosaria, Burlando, Martina, Tonini, Annalisa, Gaiani, Francesca Maria, Simoni, Lucia, Zullo, Alessandro, Fiocchi, Martina, Colombo, Delia, Zagni E., Bianchi L., Fabbrocini G., Corrao S., Offidani A., Stingeni L., Costanzo A., Pellacani G., Peris K., Bardazzi F., Argenziano G., Ruffolo S., Dapavo P., Carrera C., Fargnoli M.C., Parodi A., Romanelli M., Malagoli P., Talamonti M., Megna M., Raspanti M., Paolinelli M., Hansel K., Narcisi A., Conti A., De Simone C., Chessa M.A., De Rosa A., Provenzano E., Ortoncelli M., Moltrasio C., Fidanza R., Burlando M., Tonini A., Gaiani F.M., Simoni L., Zullo A., Fiocchi M., and Colombo D.

Subjects
Response rate, medicine.medical_specialty, Cost per responder, Biologic, Cost, Ixekizumab, Longitudinal Studie, Context (language use), Secukinumab, Severity of Illness Index, Antibodies, Indirect costs, Settore MED/35, Quality of life, Internal medicine, Psoriasis, Ustekinumab, Monoclonal, Adalimumab, Antibodies, Monoclonal, Longitudinal Studies, Quality of Life, Treatment Outcome, Italy, Humans, Biological Therapy, Real-world, medicine, health care economics and organizations, Psoriasi, Costs, business.industry, Health Policy, Research, medicine.disease, Public aspects of medicine, RA1-1270, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Human, medicine.drug
Abstract

BackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised overall direct costs of moderate-to-severe plaque psoriasis management, the annualised cost of biologic drugs and the cost per responder in the Italian National Health System perspective were assessed. More specifically, the cost per response and cost per sustained response of the most prescribed biologic therapies for the treatment of moderate-to-severe plaque psoriasis within the CANOVA study were assessed using the Psoriasis Area Severity Index (PASI) at several score levels (75, 90 and 100%).ResultsThe most frequently used biologic therapies for plaque psoriasis were secukinumab, ustekinumab, adalimumab originator, and ixekizumab. Cost of biologics was the driver of expenditure, accounting for about 98% of total costs. Adalimumab originator was the biologic with the lowest cost per responder ratio (range: €7848 - €31,378), followed by secukinumab (range: €9015 - €33,419). Ustekinumab (range: €11,689 – €39,280) and ixekizumab (range: €11,092 – €34,289) ranked respectively third and fourth, in terms of cost-effectiveness ratio. As concerns the cost per sustained response analysis, secukinumab showed the lowest value observed (€21,375) over the other options, because of its high response rate (86% vs. 60–80%), which was achieved early in time.ConclusionBiologic therapy is a valuable asset for the treatment of moderate-to-severe plaque psoriasis. Concomitant assessment of treatment costs against the expected therapeutic response over time can provide physicians and payers additional insights which can complement the traditional risk-benefit profile assessment and drive treatment decisions.

Published
2021

210. Fixed drug eruption due to melatonin.

Author

Bardazzi, F., Placucci, F., Neri, I., D'Antuono, A., and Patrizi, A.

Subjects
*SKIN diseases, *MELATONIN
Abstract

Describes the case of a fixed drug eruption of the genitalia due to melatonin. Case background; Potential risk of anaphylaxis or severe cutaneous reactions; Anticancer activity of melatonin.

Published
1998
Full Text
View/download PDF

211. Contact dermatitis due to food mite.

Author

Peluso, A.M., Bardazzi, F., Rapacchiale, S., Tardio, M., and Paganini, P.

Subjects
*ALLERGIES, *IMMUNOLOGIC diseases, *URTICARIA, *SKIN inflammation, *ASTHMA, *EPIDERMIS, *EPITHELIUM
Abstract

Prick tests with common food and inhalant allergens showed a positive reaction to Tyrophagus putrescens. In 1985, a 45-year-old entomologist presented with a seven year history of recurrent itchy papulovesiculur eruptions. The patient reported that these symptoms improved while he was away from work. Food mites can migrate under the scales of the stratum corneum or into fissures in the epidermis. Repeated exposure to such food mites may lead to sensitization, with production of urticaria or bronchial asthma.

Published
1991
Full Text
View/download PDF

212. Contact dermatitis from rubidium iodide in eyedrops.

Author

Camell, N., Bardazzi, F., Moretti, R., and Tosti, A.

Subjects
*SKIN inflammation, *SYMPTOMS, *OPHTHALMIC drugs, *SKIN diseases, *DERMATOLOGY, *CASE studies
Abstract

This article presents a case study of 70 year old man presented with sever facial dermatitis. His symptoms had appeared five months after starting on an ophthalmic preparation for the treatment of cataracts. This study has led to sum up that contact allergy to ophthalmic preparations is a common problem, preservatives being the most frequent sensitizes. The above case study also illustrates the importance of patch testing with the individual constituents of ophthalmic preparations. Negative patch test reactions to eye-drops don't exclude the possibility of contact sensitization to one or more of the ingredients of those eye-drops.

Published
1990
Full Text
View/download PDF

213. Contact dermatitis to Minoxidil.

Author

Tosti, A., Bardazzi, F., De Padova, M. P., Caponeri, G. M., Melino, M., and Veronesi, S.

Subjects
*HYPERTENSION, *CONTACT dermatitis, *MINOXIDIL, *VASODILATORS, *BALDNESS, *HAIR growth stimulants
Abstract

The article focuses on contact dermatitis due to minoxidil. It is a potent vasodilator, used for resistent hypertension, which has recently been claimed to be useful as a topical agent in the treatment of alopecia. Systemic allergic reactions have rarely been reported from oral Minoxidil. Allergic contact dermatitis has been observed in 2 patients using topical Minoxidil for hair regrowth. In the last 2 years, treatment with 1% Minoxidil lotion in 465 patients with androgenic alopecia caused 2 cases or allergic contact dermatitis and 1 of photoallergic contact dermatitis.

Published
1985
Full Text
View/download PDF

214. Lichen planus of the nails with giant cells: lichen nitidus?

Author

Fanti, P. A., Tosti, A., Morelli, R., and Bardazzi, F.

Subjects
LETTERS to the editor, LICHEN planus
Abstract

Presents a letter to the editor discussing the case of a patient with a long standing onychodystrophy with the pathological features that resembled both lichen planus and lichen nitidus.

Published
1991
Full Text
View/download PDF

216. Serological screening for coeliac disease in vitiligo and alopecia areata.

Author

Volta, U., Bardazzi, F., Zauli, D., DeFranceschi, L., Tosti, A., Molinaro, N., Ghetti, S., Tetta, C., Grassi, A., and Bianchi, F.B.

Subjects
CELIAC disease, DIGESTIVE system diseases, MALABSORPTION syndromes, GASTROENTEROLOGY, INTESTINAL diseases
Abstract

Presents a study in Great Britain on coeliac disease with skin disorders of known or suspected immunological aetiology, such as psoriasis and vitiligo. Likelihood of patients with alopecia areata to have a high risk of gluten-sensitive enteropathy. Verification of the relationship between vitiligo and gluten-sensitive enteropathy; Reason for patients positive with IgA HUC-EmA to undergo endoscopy and duodenal biopsy; Implications of sporadic associated cases according to the results of the study.

Published
1997
Full Text
View/download PDF

217. Exogenous pseudoxanthoma elasticum: a new case in an old farmer.

Author

Neri, I., Marzaduri, S., Bardazzi, F., and Patrizi, A.

Subjects
CONNECTIVE tissue diseases, FARMERS, DISEASES
Abstract

Presents a case report of an old farmer on exogenous pseudoxanthoma elasticum in the connective tissue. Identification on the mode of transmission; Characterization of the histological pattern; Non-inflammatory skin disorder of the neck and supraclavicular regions.

Published
1998
Full Text
View/download PDF

218. Atypical presentation of a blue naevus at the tip of the nose.

Author

Antonucci, A., Bardazzi, F., Balestri, R., and Misciali, C.

Subjects
*CASE studies, *NASAL tumors, *PIGMENTATION disorders, *PHOTOGRAPHIC exposure, *PATIENTS
Abstract

The article presents a case study of a 37-year-old white man diagnosed with a benign neoplasm (BN) located on the tip of his nose. The patient's job as a photographer contributed to the analysis of localized argyria which results from cutaneous exposure to silver. It also notes that the distribution of the pigmentation is atypical, wherein it was spread over the tip of the nose and there was an accentuation of the greyish pigmentation in the ostia of the hair follicle infundibula.

Published
2010
Full Text
View/download PDF

220. Penile Crohn's disease: a case report.

Author

Neri, I, Bardazzi, F, Fanti, P A, and Guidetti, M S

Abstract

Metastatic Crohn's disease is a rare inflammatory condition characterised by cutaneous granulomatous lesions separated from the affected bowel by normal intact skin. Involvement of the genitalia in Crohn's disease is rare and consists of ulcerated lesions in almost all of the cases reported in the literature. We describe a case of penile involvement in a 27 year old man with a 5 year history of Crohn's disease. Should genital involvement precede the bowel disease, patients may consult the sexually transmitted disease service for this problem and the dermatovenereologists may be the first to formulate the diagnosis. [ABSTRACT FROM PUBLISHER]

Published
1995
Full Text
View/download PDF

221. In‐depth, single‐centre, analysis of changes in emergency service access after the spread of COVID‐19 across Italy.

Author

Ferrari, T., Zengarini, C., Bardazzi, F., and Pileri, A.

Subjects
*COVID-19, *EMERGENCY medical services, *COVID-19 pandemic
Abstract

In-depth, single-centre, analysis of changes in emergency service access after the spread of COVID-19 across Italy The COVID-19 pandemic started in Italy in February 2020, and in a preliminary report,1 we described a significant decrease in visits to our dermatological emergency service (ES) in our institution. The total number of patients requiring consultation decreased significantly ( I P i < 0.05) from 1328 in the pre-pandemic period to 483 in the pandemic period (Fig. [Extracted from the article]

Published
2021
Full Text
View/download PDF

223. Graham Little-Piccardi-Lasseur Syndrome Following HBV Vaccination.

Author

Bardazzi, F., Landi, C., Orlandi, C., Neri, I., and Varotti, C.

Subjects
*HEPATITIS B vaccines, *LICHEN planus, *DRUG side effects, *DIAGNOSIS
Abstract

Focuses on the development of Graham Little-Piccardi-Lasseur syndrome after intramuscular Hepatitis B virus (HBV) vaccination. Association between HBV and lichen rubber planus (LRP); Characteristics of cutaneous or mucosal lichen planus and alopecia; Sub-units of non-infective virus.

Published
1999
Full Text
View/download PDF

224. Contact stomatitis due to N,N-dimethyl-para-toluidine.

Author

Tosti, A., Bardazzi, F., Piancastelli, E., and Brasile, G. P.

Subjects
*ALLERGIES, *POLYMERIZATION, *METHYL methacrylate, *CONTAGIOUS ecthyma, *DENTAL abutments, *PROSTHETICS
Abstract

The article focuses on contact stomatitis caused due to NN-dimethyl-para-toludine. Allergic resins are among the most widely used compound in dental practice for construction of prostheses. These resins are produced by inducing polymerization of a mixture of methyl methacrylate monomer and polymethyl methacrylate powder with benzyl peroxide and an accelerator. In this process of polymerization is rarely complete. The article presents information on a case study of a 62 year old house wife with a problem of burning and soreness of the mouth which lasted for 1 month.

Published
1990
Full Text
View/download PDF

225. Unusual complication of sensitizing therapy for alopecia areata.

Author

Fosti, A., Bardazzi, F., and Ghetti, P.

Subjects
*CONTACT dermatitis, *ALOPECIA areata, *ACETONE, *DINITROCHLOROBENZENE, *OCCUPATIONAL hazards, *PATIENTS
Abstract

This article presents a case study of 36-year-old woman suffering from patchy alopecia areata. It was found out that she was sensitized to acetone for a therapy. After handling acetone at work the patient developed an acute contact dermatitis of the face and upper limbs. The patient was patch tested and it was observed that she showed positive reactions to acetone which persisted for 7 days. the problem of subsequent occupational hazards in patients submitted to sensitizing therapies seemed to have been definitely resolved when squaric acid dibutylester and diphencyprone were introduced to substitute for dinitrochlorobenzene.

Published
1988
Full Text
View/download PDF

226. Immediate contact dermatitis in food handlers.

Author

Tosh, A., Fanti, P. A., Guerra, L., Peluso, A. M., and Bardazzi, F.

Subjects
OCCUPATIONAL disease diagnosis, ECZEMA, FOOD handling, IMMUNOHISTOCHEMISTRY, LANGERHANS cells, SKIN biopsy
Abstract

Since January 1987, 63 food handlers affected by chronic hand eczema were studied. A large variety of foods including fruits, vegetables, fish and meat elicited the positive vesicular reaction in different patients. The histological and immunohistochemical study of apparently normal hand skin showed focal parakeratosis and an increased number of Langerhans cells. Biopsies of the immediate vesicular reactions induced by foods showed spongiotic vesicles within the epidermis and a moderate to dense mononuclear dermal perivascular infiltrate.

Published
1990
Full Text
View/download PDF

227. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iris, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study group, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, Vezzoni R, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo', S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study, Group, Balestri, R, Bernardini, N, Belloni Fortini, A, Burlando, M, Caldarola, G, Campione, E, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, Mt, Franchi, C, Esposito, M, Foti, C, Gambini, Dm, Gambardella, A, Girolomoni, G, Giunta, A, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, Ml, Patrizi, A, Pellacani, G, Richetta, Ag, Rosi, E, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Venturini, M, Vezzoni, R, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Piaserico S., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Rossi M.T., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo' S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., and Peris K.

Subjects
0301 basic medicine, Male, Clinical Biochemistry, Disease, Cohort Studies, 0302 clinical medicine, Drug Discovery, Receptors, 80 and over, Medicine, Aged, 80 and over, education.field_of_study, Incidence (epidemiology), Incidence, Interleukin-17, psoriasis, Middle Aged, dermatology, sars-CoV-2, Italy, biological therapy, 030220 oncology & carcinogenesis, Cohort, Biological Product, COVID-19, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Adult, Aged, Biological Products, Biological Therapy, Chronic Disease, Humans, Pandemics, Psoriasis, Receptors, Interleukin, Risk Assessment, Tumor Necrosis Factor-alpha, Young Adult, Cohort study, Human, medicine.medical_specialty, Population, 03 medical and health sciences, Settore MED/35, Internal medicine, education, Pharmacology, Psoriasi, Pandemic, business.industry, Biological product, Interleukin, medicine.disease, Clinical trial, 030104 developmental biology, SARS-CoV-2, Cohort Studie, business
Abstract

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

228. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Giulio Gualdi, Andrea Conti, Riccardo Balestri, Maria Rita Bongiorno, Annalisa Patrizi, Giuseppe Micali, Paolo Dapavo, Elia Rosi, M.T. Fierro, Luca Bianchi, S. Di Nuzzo, Matteo Megna, Angelo Cattaneo, R. Vezzoni, Francesca Prignano, C. Hansel, Sandra Giustini, Antonio Giovanni Richetta, A. Gambardella, Claudio Guarneri, S.P. Cannavò, Martina Burlando, Luca Stingeni, Giovanna Tilotta, K. Peris, S. Dastoli, Giulia Rech, Giuseppe Argenziano, Claudio Feliciani, Marina Venturini, Angelo V. Marzano, Paolo Gisondi, Giampiero Girolomoni, Mariateresa Rossi, D.M. Gambini, Maurizio Lombardo, Rossana Tiberio, Concetta Potenza, Lidia Sacchelli, Elisabetta Botti, Andrea Carugno, Marco Galluzzo, Paolo Pigatto, Maria Letizia Musumeci, F. Bardazzi, Pietro Quaglino, Pietro Rubegni, Iris Zalaudek, Nicoletta Bernardini, Andrea Chiricozzi, Mark S. Talamonti, Caterina Foti, Giovanni Pellacani, C. De Simone, Emanuele Trovato, Paolo Amerio, Giacomo Caldarola, A. Belloni Fortina, Federico Diotallevi, M C Fargnoli, Francesco Loconsole, Paola Savoia, Arianna Zangrilli, Stefano Piaserico, Andrea Parodi, A. M. Offidani, Steven Paul Nisticò, Gabriella Fabbrocini, Franco Rongioletti, Rosaria Fidanza, Cristina Mugheddu, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, G., Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, C., Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Marzano, A V, Bongiorno, Mr, Fargnoli, Mc, Nisticò, Sp, Cannavò, Sp, Fierro, Mt, Gambini, Dm, Musumeci, Ml, Richetta, Ag, Rossi, Mt, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M.T., Fidanza R., Foti C., Gambini D.M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel C., Megna M., Mugheddu C., Musumeci M.L., Patrizi A., Pellacani G., Piaserico S., Richetta A.G., Rosi E., Rossi M.T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A.

Subjects
medicine.medical_specialty, Tildrakizumab, Biolgical therapy, COVID-19, Psoriasis, Settore MED/35, Chronic Disease, Emergencies, Humans, Italy, Biological Therapy, Ustekinumab, medicine, Adalimumab, biologics, Intensive care medicine, Letter to the Editor, psoriasi, psoriasis, covid-19, pandemic, Emergencie, Psoriasi, Risankizumab, business.industry, SARS-CoV-2, medicine.disease, dermatology, Ixekizumab, Guselkumab, Infectious Diseases, Secukinumab, business, Settore MED/35 - MALATTIE CUTANEE E VENEREE, biologic, COVID-19, psoriasis, biological therapies, medicine.drug, Human
Abstract

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

Published
2020

230. Sifilide congenita: come riconoscerla e come comportarsi.

Author

D'Antuono, A., Zauli, S., Bardazzi, F., Ismaili, A., Negosanti, F., and Bonifazi, E.

Abstract

La sifilide può seriamente compromettere una gravidanza causando aborti spontanei, ritardi di crescita intrauterina, morte perinatale. I neonati da madri infette possono essere asintomatici o presentare un quadro variabile di segni e sintomi, che un clinico non esperto può non riconoscere come sifilide congenita. I neonati asintomatici possono essere infetti e richiedere una terapia specifica oppure possono presentare degli anticorpi trasmessi passivamente dalla madre senza avere alcuna infezione. Queste differenti situazioni richiedono un diverso approccio diagnostico e terapeutico. [ABSTRACT FROM AUTHOR]

Published
2009

231. Italian guidelines in diagnosis and treatment of alopecia areata

Author

Marta Muscianese, Giuseppe Monfrecola, Alfredo De Rossi, Stefano Astorino, Valentina Garelli, Francesco Lacarrubba, Annunziata Dattola, Giuseppe Micali, Andrea D'Arino, Alessandro Federico, Simone Garcovich, Luca Stingeni, Oriana Simonetti, Federico Bardazzi, Norma Cameli, Francesca Magri, Stefano Piaserico, Marta Carlesimo, Elena Marinello, Victor Desmond Mandel, Antonella Di Cesare, Katharina Hansel, Stefano Caccavale, Roberto D'Ovidio, Emi Dika, Annamaria Offidani, Donato Di Nunno, Flavia Pigliacelli, Lucia Villa, Cosimo Misciali, Teodora R Stan, Graziana Amendolagine, Colombina Vincenzi, Viviana Lora, Niccolò Rivetti, Maria Beatrice de Felici del Giudice, Maria Caterina Fortuna, Marina Talamonti, Claudio Feliciani, Cristina Guerriero, Alessandro Borghi, Francesca Bruni, Elisabetta Fulgione, Gabriella Fabbrocini, Andrea Carugno, Maria Carmela Annunziata, Paola Monari, Francesco Tassone, Gemma Caro, Maria C Arisi, Piergiacomo Calzavara-Pinton, Matteo Megna, Annalisa Patrizi, Graziella Babino, Bianca Maria Piraccini, Stefano Calvieri, Anna Belloni Fortina, Manuela Papini, Gloria Orlando, Stefania Barruscotti, Michele Cardone, Aurora Alessandrini, Iria Neri, Rosa Coppola, Michelangelo La Placa, Marco Galluzzo, Michela Starace, A Rossi, M Muscianese, BM Piraccini, M Starace, M Carlesimo, VD Mandel, A Alessandrini, S Calvieri, G Caro, A D’arino, A Federico, F Magri, F Pigliacelli, G Amendolagine, MC Annunziata, MC Arisi, G Babino, F Bardazzi, S Barruscotti, A Belloni Fortina, A Borghi, F Bruni, S Caccavale, P Calzavara Pinton, N Cameli, A Carugno, R Coppola, A Dattola, MB De Felici Del Giudice, A Di Cesare, E Dika, R D’ovidio, G Fabbrocini, C Feliciani, E Fulgione, M Galluzzo, S Garcovich, V Garelli, C Guerriro, K Hansel, M La Placa, F Lacarrubba, V Lora, E Marinello, M Megna, G Micali, C Misciali, G Monfrecola, I Neri, A Offidani, G Orlando, M Papini, A Patrizi, S Piaserico, N Rivetti, O Simonetti, TR Stan, L Stingeni, M Talamonti, F Tassone, L Villa, C Vincenzi, MC Fortuna, Rossi, A, Muscianese, M, Piraccini, B, Starace, M, Carlesimo, M, Mandel, V, Alessandrini, A, Calvieri, S, Caro, G, D'Arino, A, Federico, A, Magri, F, Pigliacelli, F, Amendolagine, G, Annunziata, M, Arisi, M, Astorino, S, Babino, G, Bardazzi, F, Barruscotti, S, Belloni Fortina, A, Borghi, A, Bruni, F, Caccavale, S, Calzavara-Pinton, P, Cameli, N, Cardone, M, Carugno, A, Coppola, R, Dattola, A, De Felici Del Giudice, M, Di Cesare, A, Dika, E, Dinunno, D, D'Ovidio, R, Fabbrocini, G, Feliciani, C, Fulgione, E, Galluzzo, M, Garcovich, S, Garelli, V, Guerriero, C, Hansel, K, La Placa, M, Lacarrubba, F, Lora, V, Marinello, E, Megna, M, Micali, G, Misciali, C, Monari, P, Monfrecola, G, Neri, I, Offidani, A, Orlando, G, Papini, M, Patrizi, A, Piaserico, S, Rivetti, N, Simonetti, O, Stan, T, Stingeni, L, Talamonti, M, Tassone, F, Villa, L, Vincenzi, C, Fortuna, M, Rossi, Alfredo, Muscianese, Marta, Piraccini, Bianca M, Starace, Michela, Carlesimo, Marta, Mandel, Victor D, Alessandrini, Aurora, Calvieri, Stefano, Caro, Gemma, D'Arino, Andrea, Federico, Alessandro, Magri, Francesca, Pigliacelli, Flavia, Amendolagine, Graziana, Annunziata, Maria C, Arisi, Maria Chiara, Babino, Graziella, Bardazzi, Federico, Barruscotti, Sefania, Belloni Fortina, Anna, Borghi, Alessandro, Bruni, Francesca, Caccavale, Stefano, Calzavara Pinton, Piergiacomo, Cameli, Norma, Carugno, Andrea, Coppola, Rosa, Dattola, Annunziata, De Felici Del Giudice, Maria B, Di Cesare, Antonella, Dika, Emi, D'Ovidio, Roberto, Fabbrocini, Gabriella, Feliciani, Claudio, Fulgione, Elisabetta, Galluzzo, Marco, Garcovich, Simone, Garelli, Valentina, Guerriro, Cristina, Hansel, Katharina, La Placa, Michelangelo, Lacarrubba, Francesco, Lora, Viviana, Marinello, Elena, Megna, Matteo, Micali, Giuseppe, Misciali, Cosimo, Monfrecola, Giuseppe, Neri, Iria, Offidani, Annamaria, Orlando, Gloria, Papini, Manuela, Patrizi, Annalisa, Piaserico, Stefano, Rivetti, Niccolo', Simonetti, Oriana, Stan, Teodora R, Stingeni, Luca, Talamonti, Maria, Tassone, Francesco, Villa, Lucia, Vincenzi, Colombina, Fortuna, Maria C, Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., Alessandrini, A., Calvieri, S., Caro, G., D'Arino, A., Federico, A., Magri, F., Pigliacelli, F., Amendolagine, G., Annunziata, M. C., Arisi, M. C., Astorino, S., Babino, G., Bardazzi, F., Barruscotti, S., Belloni Fortina, A., Borghi, A., Bruni, F., Caccavale, S., Calzavara-Pinton, P., Cameli, N., Cardone, M., Carugno, A., Coppola, R., Dattola, A., De Felici Del Giudice, M. B., Di Cesare, A., Dika, E., Dinunno, D., D'Ovidio, R., Fabbrocini, G., Feliciani, C., Fulgione, E., Galluzzo, M., Garcovich, S., Garelli, V., Guerriero, C., Hansel, K., La Placa, M., Lacarrubba, F., Lora, V., Marinello, E., Megna, M., Micali, G., Misciali, C., Monari, P., Monfrecola, G., Neri, I., Offidani, A., Orlando, G., Papini, M., Patrizi, A., Piaserico, S., Rivetti, N., Simonetti, O., Stan, T. R., Stingeni, L., Talamonti, M., Tassone, F., Villa, L., Vincenzi, C., and Fortuna, M. C.

Subjects
medicine.medical_specialty, corticosteroid, Alopecia Areata, MEDLINE, Socio-culturale, Alopecia areata, Autoimmunity, Guideline, Autoimmune Diseases, Evidence-Based Medicine, Hair Follicle, Italy, Alopecia areata, Autoimmunity, Dermatology, Disease, Minoxidil, Guideline, Autoimmune Disease, Autoimmune Diseases, Food and drug administration, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Settore MED/35, Evidence-Based Medicine, Hair Follicle, Humans, Italy, alopecia areata, autoimmunity, guideline, autoimmune diseases, evidence-based medicine, hair follicle, humans, italy, Medicine, topical immunotherapy, integumentary system, business.industry, trichoscopy, Evidence-based medicine, medicine.disease, Trichoscopy, Clinical trial, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Human, medicine.drug
Abstract

Alopecia Areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration (FDA). The Italian Study Group for Cutaneous Annexial Disease of the Italian Society of dermatology (SIDeMaST) proposes these Italian guidelines for diagnosis and treatment of Alopecia Areata deeming useful for the daily management of the disease. This article summarizes evidence-based treatment associated with expert-based recommendations.

Published
2019

232. Brodalumab for the treatment of moderate‐to‐severe plaque‐type psoriasis: a real‐life, retrospective 24‐week experience.

Author

Fargnoli, M.C., Esposito, M., Dapavo, P., Parodi, A., Rossi, M., Tiberio, R., Dastoli, S., Offidani, A.M., Argenziano, G., Gisondi, P., Lo Schiavo, A., Loconsole, F., Pella, P., Bardazzi, F., Cusano, F., Gattoni, M., Nacca, M., Cannavò, S.P., Pellegrini, C., and Costanzo, A.

Subjects
*PSORIASIS, *PATIENT satisfaction, *AGE of onset, *DISEASE duration, *PATIENT safety
Abstract

Background: Brodalumab was efficacious and safe in moderate‐to‐severe plaque‐type psoriasis in the AMAGINE trials; published reports under real‐life conditions are limited. Objectives: To evaluate the effectiveness and safety of brodalumab in patients with moderate‐to‐severe plaque‐type psoriasis in a real‐world setting. Methods: This observational, retrospective study enrolled adult patients (≥18 years) with moderate‐to‐severe plaque‐type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded. Results: Seventy‐eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P < 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio‐experienced patients, including those who had failed on anti‐interleukin (IL)‐17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P < 0.0001 and P < 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow‐up (n = 1) and surgical procedure (n = 1). Conclusions: Brodalumab is effective and safe in the treatment of moderate‐to‐severe psoriasis in a real‐world setting, including in patients with failure to anti‐IL17 therapies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

234. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Author

Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G. Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi, Gargiulo, L, Ibba, L, Malagoli, P, Angileri, R G, Bardazzi, F, Bernardini, N, Burlando, M, Carrera, C G, Chiricozzi, A, Dapavo, P, Dini, V, Fabbrocini, G, Gaiani, F M, Galluzzo, M, Giofré, C, Guarneri, C, Loconsole, F, Malara, G, Marcelli, L, Megna, M, Piaserico, S, Talamonti, M, Costanzo, A, and Narcisi, A

Subjects
Infectious Diseases, Dermatology
Abstract

Background: Guselkumab is a humanized monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. Objectives: We conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real-life setting. Methods: Our retrospective study included 233 adults affected by moderate-to-severe plaque psoriasis, enrolled in 14 different Italian centers, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered. Results: At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤ 2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult-to-treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI≤2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult-to-treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study. Conclusion: Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in "real-life" clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.

Published
2023

235. Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy.

Author

Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A.V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M.R., and Feliciani, C.

Subjects
*COVID-19, *BIOTHERAPY, *MEDICAL personnel, *PSORIASIS
Abstract

Discontinuation rates ranged from 1.4% for patients using guselkumab to 5.5% for those treated with infliximab, when the decision was taken by the patients, while ranged between 0.5% for ixekizumab-treated patients and 2.8% for adalimumab-treated when the decision was taken after dermatological consultation. Patients and dermatologists are satisfied using biologics for psoriasis treatment. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. [Extracted from the article]

Published
2020
Full Text
View/download PDF

237. Merkel cell carcinoma: a prompt diagnosis to increase survival.

Author

Chessa, M.A., Malosso, M., Pepe, F., Patrizi, A., Telo, S., Ambrosini, V., Fanti, S., Magnano, M., Baraldi, C., Corti, B., Filippi, F., Vaccari, S., Pileri, A., and Bardazzi, F.

Subjects
*MERKEL cell carcinoma, *PANCREATIC tumors, *CANCER remission
Abstract

Merkel cell carcinoma (MCC) is a rare, malignant tumour related to advanced age and immunusoppression.[[1]] Its incidence has been increased over decades, but management is still controversial.[[1]] Looking for MCC cases over the last 10 years, nine cases were retrieved (six females and three males, median age 71 years; for clinical data, see Table).[3] A red-pink nodule was observed in five cases, a blue-violaceous lesion was present in three instances, while the remaining patient presented with a skin-coloured nodule. MCC patients can perform SP 18 sp F-FDG-PET/CT in staging to identify and quantify nodal or distant metastasis or during the follow-up. [Extracted from the article]

Published
2019
Full Text
View/download PDF

238. Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab

Author

F. Bruni, F. Bardazzi, M. Roda, C. Bellusci, Beatrice Raone, Corrado Zengarini, Costantino Schiavi, Zengarini C., Roda M., Schiavi C., Bruni F., Bardazzi F., Bellusci C., and Raone B.

Subjects
genetic structures, business.industry, Elevated serum IgE, Dermatology, Omalizumab, Atopic dermatitis, medicine.disease, eye diseases, body regions, medicine.anatomical_structure, Chronic inflammatory skin condition, Immunology, Elevated IgE levels, medicine, vernal keratoconjunctivitis, atopic dermatitis, omalizumab, sense organs, Corneal scarring, business, Vernal keratoconjunctivitis, Sensitization, medicine.drug
Abstract

Atopic Dermatitis (AD) is a chronic inflammatory skin condition, defined as extrinsic when associated with elevated serum IgE levels and sensitization to various allergens1 . It is linked to multiple allergic disorders; among them, Vernal keratoconjunctivitis (VKC) is one of the worst affecting the eyes, which may lead to corneal scarring and vision loss if not treated properly.

Published
2021

239. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Author

Luca Stingeni, Andrea Chiricozzi, Piergiorgio Malagoli, Anna Campanati, Marina Venturini, Antonio Costanzo, Anna Balato, Paolo Gisondi, Clara De Simone, Giampiero Girolomoni, Maria Letizia Musumeci, Aurora Parodi, Franco Rongioletti, Angelo Cattaneo, Claudia Lasagni, Santo Raffaele Mercuri, Valentina Dini, Francesca Prignano, Federico Bardazzi, Concetta Potenza, Claudio Guarneri, Ada Lo Schiavo, Ketty Peris, A. M. Offidani, Manuela Papini, Paolo Dapavo, Francesco Loconsole, Maria Laura Flori, Francesco Cusano, Maria Concetta Fargnoli, Stefano Piaserico, Marco Galluzzo, Paolo Amerio, Piergiacomo Calzavara Pinton, Luca Bianchi, Marina Talamonti, Luigi Naldi, Rossana Tiberio, G. Malara, Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria C, Flori, Maria L, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Lo Schiavo, Ada, Malagoli, Piergiorgio, Malara, Giovanna, Mercuri, Santo R, Musumeci, Maria L, Naldi, Luigi, Papini, Manuela, Parodi, Aurora, Potenza, Concetta, Prignano, Francesca, Rongioletti, Franco, Stingeni, Luca, Tiberio, Rossana, Venturini, Marina, Bianchi, Luca, Costanzo, Antonio, Cusano, Francesco, Girolomoni, Giampiero, Offidani, Anna M, Peris, Ketty, Gisondi, P., Talamonti, M., Chiricozzi, A., Piaserico, S., Amerio, P., Balato, A., Bardazzi, F., Calzavara Pinton, P., Campanati, A., Cattaneo, A., Dapavo, P., De Simone, C., Dini, V., Fargnoli, M. C., Flori, M. L., Galluzzo, M., Guarneri, C., Lasagni, C., Loconsole, F., Lo Schiavo, A., Malagoli, P., Malara, G., Mercuri, S. R., Musumeci, M. L., Naldi, L., Papini, M., Parodi, A., Potenza, C., Prignano, F., Rongioletti, F., Stingeni, L., Tiberio, R., Venturini, M., Bianchi, L., Costanzo, A., Cusano, F., Girolomoni, G., Offidani, A. M., and Peris, K.

Subjects
Quality of life, Moderate to severe, medicine.medical_specialty, Consensus, Delphi method, Consensu, Dermatology, Plaque psoriasis, Systemic inflammation, Treat-to-target, 030207 dermatology & venereal diseases, 03 medical and health sciences, Settore MED/35, 0302 clinical medicine, Quality of life (healthcare), Psoriasis Area and Severity Index, Psoriasis, consensus, plaque psoriasis, quality of life, systemic inflammation, treatto-target, medicine, Intensive care medicine, Original Research, business.industry, Treat to target, Dermatology Life Quality Index, medicine.disease, Plaque psoriasi, 030220 oncology & carcinogenesis, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract

Introduction: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations. Methods: On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement). Results: Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy. Conclusion: These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.

Published
2021

240. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)

Author

Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Valentina Dini, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Alessandra Narcisi, Francesca Sampogna, Massimo Travaglini, Antonio Costanzo, Malagoli, P., Dapavo, P., Pavia, G., Amoruso, F., Argenziano, G., Bardazzi, F., Burlando, M., Carrera, C. G., Damiani, G., Dini, V., Girolomoni, G., Guarneri, C., Loconsole, F., Narcisi, A., Sampogna, F., Travaglini, M., and Costanzo, A.

Subjects
real-life experience, Interleukin-17, Dermatology, General Medicine, Antibodies, Monoclonal, Humanized, Severity of Illness Index, long-term efficacy, Treatment Outcome, ixekizumab, Quality of Life, Humans, Psoriasis, Dermatologic Agents, Retrospective Studies
Abstract

Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients' quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate-to-severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL-17A with high specificity and affinity. Inhibiting IL-17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease. Long-term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate-to-severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow-up of care until 192 weeks.

Published
2022

241. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.

Author

Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, A., Costanzo, A., Conti, A., Dapavo, P., De Simone, C., Foti, C., Naldi, L., Offidani, A., Parodi, A., Piaserico, S., Prignano, F., Rongioletti, F., Stingeni, L., Talamonti, M., and Girolomoni, G.

Subjects
*PSORIASIS treatment, *MEDICAL protocols, *PUBLIC health, *EVIDENCE-based medicine, *DERMATOLOGISTS
Abstract

Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

242. Natural history of isolated nail psoriasis and its role as a risk factor for the development of psoriatic arthritis: a single-centre cross-sectional study.

Author

Balestri, R., Rech, G., Rossi, E., Starace, M., Malavolta, N., Bardazzi, F., Patrizi, A., and Piraccini, B.M.

Subjects
*PSORIASIS, *PSORIASIS treatment, *PSORIATIC arthritis, *CROSS-sectional method, *CLINICAL trials, *PATIENTS, *DISEASE risk factors
Abstract

The article presents a research letter on natural history of isolated nail psoriasis and its role as a risk factor for the development of psoriatic arthritis. It discusses a single-centre cross-sectional study for evaluating natural history of isolated nail psoriasis; and clinical appearance of psoriatic arthritis (PsA).

Published
2017
Full Text
View/download PDF

243. Idiopathic granulomatous vulvitis and subsequent oral granulomatosis: a diagnostic and therapeutic challenge.

Author

Sacchelli, L., Tengattini, V., Baraldi, C., Filippi, F., Loi, C., Ferrara, F., Patrizi, A., and Bardazzi, F.

Subjects
*SEXUALLY transmitted diseases, *CROHN'S disease
Abstract

The article presents the case study of the 47-year-old white woman suffering from persistent swelling of the labia majora, diffuse lichenification of the perineal and pubic area, alopecia of the pubic hair and multiple erosions involving the perianal area. The is identified as the case of Granulomatous vulvitis (GV) and anogenital granulomatosis (AGG) that are rare inflammatory, chronic, relapsing erythema, oedema and ulcerations in the genitoperineal area.

Published
2019
Full Text
View/download PDF

244. Multiple itchy blisters and painful erosions on the hands

Author

Marco Adriano Chessa, Camilla Loi, Federico Bardazzi, Michela Magnano, Carlotta Baraldi, Annalisa Patrizi, Federica Filippi, Chessa M.A., Filippi F., Baraldi C., Magnano M., Loi C., Patrizi A., and Bardazzi F.

Subjects
medicine.medical_specialty, business.industry, Medicine, Blisters, Dermatology, medicine.symptom, business
Published
2020

245. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis

Author

Paolo GISONDI, Maria C. FARGNOLI, Paolo AMERIO, Giuseppe ARGENZIANO, Federico BARDAZZI, Luca BIANCHI, Andrea CHIRICOZZI, Andrea CONTI, Monica CORAZZA, Antonio COSTANZO, Paolo DAPAVO, Clara DE SIMONE, Gabriella FABBROCINI, Claudio FELICIANI, Caterina FOTI, Giampiero GIROLOMONI, Claudio GUARNERI, Angelo V. MARZANO, Giuseppe MICALI, Annamaria OFFIDANI, Aurora PARODI, Giovanni PELLACANI, Stefano PIASERICO, Francesca PRIGNANO, Marco ROMANELLI, Franco RONGIOLETTI, Pietro RUBEGNI, Giuseppe STINCO, Luca STINGENI, Carlo F. TOMASINI, Marina VENTURINI, Ketty PERIS, Piergiacomo CALZAVARA-PINTON, Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, A., Conti, A., Corazza, M., Costanzo, A., Dapavo, P., DE Simone, C., Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, K., and Calzavara-Pinton, P.

Subjects
Pandemic, Female, Humans, Pandemics, Pregnancy, SARS-CoV-2, Ustekinumab, COVID-19, Psoriasis, Biological products, Guideline, Therapeutics, Dermatology, Infectious Diseases, Settore MED/35, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human
Abstract

SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by moderate to severe plaque psoriasis. The content of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline, suggestions for disease severity grading and treatment goals. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs including acitretin, cyclosporine, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. Moreover, the guideline provides guidance for specific clinical situations such as patient with concomitant psoriatic arthritis, inflammatory bowel disease, a history of malignancies, a history of depression, diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or those with childbearing potential. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

Published
2022

246. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study—IL PSO (Italian landscape psoriasis)

Author

Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, Luciano Ibba, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Francesca Sampogna, Massimo Travaglini, Piergiorgio Malagoli, Antonio Costanzo, Narcisi, A., Valenti, M., Gargiulo, L., Ibba, L., Amoruso, F., Argenziano, G., Bardazzi, F., Burlando, M., Carrera, C. G., Damiani, G., Dapavo, P., Dini, V., Franchi, C., Girolomoni, G., Guarneri, C., Loconsole, F., Sampogna, F., Travaglini, M., Malagoli, P., and Costanzo, A.

Subjects
Infectious Diseases, Dermatology, psoriasis, Biologics, psoriasis, psoriasis treatment, Biologics, psoriasis treatment
Abstract

Background: Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin-23. It is approved for treatment of moderate–severe chronic plaque psoriasis. Objectives: We conducted a 52-week retrospective study to assess the effectiveness and safety of tildrakizumab in a real-life setting. Methods: Our retrospective study included 237 consecutive adults with moderate-to-severe plaque psoriasis, enrolled in 10 different Italian centres, treated with tildrakizumab up to Week 52. Patient characteristics, comorbidities, previous treatments and the PASI (Psoriasis Area and Severity Index) score at each visit (baseline, Week 16, Week 28 and Week 52) were retrieved from the electronic medical records. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI with respect to baseline PASI were registered. Results: At Week 52, 90.91%, 73.55% and 58.68% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. An absolute PASI ≤ 2 was reached by 85.95% at Week 52. Compared with Phase 3 clinical trials, we observed similar rates of PASI 75/90 responses and higher percentages of patients achieving PASI 100. Patients who had not responded to previous biologic treatments and patients with cardio-metabolic comorbidities were significantly more likely to achieve PASI 100 at Week 28 and PASI 90 at Week 52. The higher body mass index did not interfere with the odds of reaching PASI 75/90/100 at each time point. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment because of adverse events. Conclusion: Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in ‘real-life’ clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52.

Published
2022

247. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study

Author

Delia, Colombo, Luca, Bianchi, Gabriella, Fabbrocini, Salvatore, Corrao, Annamaria, Offidani, Luca, Stingeni, Antonio, Costanzo, Giovanni, Pellacani, Ketty, Peris, Federico, Bardazzi, Giuseppe, Argenziano, Silvana, Ruffolo, Paolo, Dapavo, Carlo, Carrera, Maria Concetta, Fargnoli, Aurora, Parodi, Marco, Romanelli, Piergiorgio, Malagoli, Marina, Talamonti, Matteo, Megna, Massimo, Raspanti, Matteo, Paolinelli, Katharina, Hansel, Alessandra, Narcisi, Andrea, Conti, Clara, De Simone, Marco Adriano, Chessa, Alina, De Rosa, Eugenio, Provenzano, Michela, Ortoncelli, Chiara, Moltrasio, Rosaria, Fidanza, Martina, Burlando, Annalisa, Tonini, Francesca Maria, Gaiani, Lucia, Simoni, Alessandra, Ori, Martina, Fiocchi, Emanuela, Zagni, Colombo, Delia, Bianchi, Luca, Fabbrocini, Gabriella, Corrao, Salvatore, Offidani, Annamaria, Stingeni, Luca, Costanzo, Antonio, Pellacani, Giovanni, Peris, Ketty, Bardazzi, Federico, Argenziano, Giuseppe, Ruffolo, Silvana, Dapavo, Paolo, Carrera, Carlo, Fargnoli, Maria Concetta, Parodi, Aurora, Romanelli, Marco, Malagoli, Piergiorgio, Talamonti, Marina, Megna, Matteo, Raspanti, Massimo, Paolinelli, Matteo, Hansel, Katharina, Narcisi, Alessandra, Conti, Andrea, De Simone, Clara, Chessa, Marco Adriano, De Rosa, Alina, Provenzano, Eugenio, Ortoncelli, Michela, Moltrasio, Chiara, Fidanza, Rosaria, Burlando, Martina, Tonini, Annalisa, Gaiani, Francesca Maria, Simoni, Lucia, Ori, Alessandra, Fiocchi, Martina, Zagni, Emanuela, Colombo, D., Bianchi, L., Fabbrocini, G., Corrao, S., Offidani, A., Stingeni, L., Costanzo, A., Pellacani, G., Peris, K., Bardazzi, F., Argenziano, G., Ruffolo, S., Dapavo, P., Carrera, C., Fargnoli, M. C., Parodi, A., Romanelli, M., Malagoli, P., Talamonti, M., Megna, M., Raspanti, M., Paolinelli, M., Hansel, K., Narcisi, A., Conti, A., De Simone, C., Chessa, M. A., De Rosa, A., Provenzano, E., Ortoncelli, M., Moltrasio, C., Fidanza, R., Burlando, M., Tonini, A., Gaiani, F. M., Simoni, L., Ori, A., Fiocchi, M., and Zagni, E.

Subjects
Adult, Male, real-world, Biological Products, biologics, effectiveness, patient-reported outcomes, plaque psoriasis, Severity of Illness Index, Plaque psoriasi, Treatment Outcome, Settore MED/35, Patient-Reported Outcome, Quality of Life, Humans, Psoriasis, Female, Longitudinal Studies, Prospective Studies, Settore MED/35 - MALATTIE CUTANEE E VENEREE, biologic, effectivene
Abstract

EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional (CANOVA) study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate–severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate–severe plaque psoriasis, who started a biologic treatment between 24 weeks and 24 months before enrolment, were included. With a follow-up visit at 6months after enrolment, each patient had at least 12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life, and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%–89%) at 16 weeks, 90% (87%–93%) at 24 weeks, and 91% (89%–94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%–79%) and 53% (49%–57%), respectively. Sustained PASI 75 response after 1year from treatment start was achieved by 78% (74%–82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients.

Published
2022

248. Secukinumab in multi-failure psoriatic patients: the last hope?

Author

Magnano, M., Loi, C., Patrizi, A., Sgubbi, P., Bardazzi, F., Balestri, R., Rech, G., Tasin, L, Girardelli, C. R., Conti, A., Odorici, G., Campanati, A., and Offidani, A. M.

Subjects
*PSORIASIS treatment, *DISEASE risk factors, *PSORIASIS, *CYCLOSPORINE, *TUMOR necrosis factors, *THERAPEUTIC use of monoclonal antibodies, *PATIENTS
Abstract

Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also these agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a human monoclonal antibody that selectively neutralizes interleukin-17 A and is recently approved for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

250. The impact of psoriasis on quality of life of children and their caregivers: an Italian experience

Author

Federica Filippi, Annalisi Patrizi, Faraz M. Ali, Marica Iommi, Vera Tengattini, Marco Adriano Chessa, Federico Bardazzi, Iria Neri, Paola Rucci, Bardazzi F., A Chessa M., Patrizi A., Iommi M., Rucci P., M Ali F., Filippi F., Tengattini V., and Neri I.

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, business.industry, Administration, Topical, MEDLINE, Dermatology, psoriasis, medicine.disease, Health Surveys, Severity of Illness Index, Quality of life (healthcare), Caregivers, Italy, Child, Preschool, Family medicine, Psoriasis, Quality of Life, medicine, Humans, Female, Dermatologic Agents, Child, business
Abstract

non disponibile

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results